Pharmaceutical

Risk adjusted net present value: What is the current valuation of Merck’s MK-0616?

MK-0616 is a peptide commercialized by Merck, with a leading Phase III program in Heterozygous familial hypercholesterolemia (heFH).

Sep 19, 2023 - 20:00
Risk adjusted net present value: What is the current valuation of Merck’s MK-0616?
MK-0616 is a peptide commercialized by Merck, with a leading Phase III program in Heterozygous familial hypercholesterolemia (heFH).
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of AstraZeneca’s ...

Next Article

Kroger Health Joins Hands With Performance Kitchen to Provide Medically Tailored...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: KRAS, the ideal cancer drug target that became ‘undruggable,’ takes on a new glow

STAT+: KRAS, the ideal cancer drug target that became ‘...

Aug 31, 2023

Valneva pushes FDA approval date for chikungunya vaccine

Valneva pushes FDA approval date for chikungunya vaccine

Aug 14, 2023

NorthSea Therapeutics bags FDA rare paediatric disease tag for NASH drug

NorthSea Therapeutics bags FDA rare paediatric disease ...

Oct 17, 2023